CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases

被引：7

作者：

Chevalier, Kevin ^{[1
]}

Genin, Michael ^{[2
]}

Jean, Thomas Petit ^{[3
]}

Avouac, Jerome ^{[4
]}

Flipo, Rene-Marc ^{[5
]}

Georgin-Lavialle, Sophie ^{[6
]}

El Mahou, Soumaya ^{[7
]}

Pertuiset, Edouard ^{[8
]}

Pham, Thao ^{[9
]}

Servettaz, Amelie ^{[10
]}

Marotte, Hubert ^{[11
]}

Domont, Fanny ^{[12
]}

Chazerain, Pascal ^{[13
]}

Devaux, Mathilde ^{[14
]}

Mekinian, Arsene ^{[15
]}

Sellam, Jeremie ^{[16
]}

Fautrel, Bruno ^{[17
]}

Rouzaud, Diane ^{[18
]}

Ebstein, Esther ^{[19
]}

Costedoat-Chalumeau, Nathalie ^{[20
]}

Richez, Christophe ^{[21
]}

Hachulla, Eric ^{[22
]}

Mariette, Xavier ^{[1
]}

Seror, Raphaele ^{[1
]}

机构：

[1] Univ Paris Saclay, Hop Bicetre, Ctr Immunol Viral Infect & Autoimmune Dis, INSERM,UMR 1184,Dept Rheumatol,AP HP, Le Kremlin Bicetre, France

[2] Univ Lille, CHU Lille, ULR METRICS Evaluat Technol St & Prat Med 2694, Lille, France

[3] AP HP, Dept Innovat & Donnees, Paris, France

[4] Cochin Hosp, Rheumatol A, Paris, France

[5] Univ Lille, Rheumatol, Lille, France

[6] Tenon Hosp, Internal Med, Paris, France

[7] Hosp Ctr Tourcoing, Rheumatol, Tourcoing, France

[8] Hosp Rene Dubos, Rheumatol, Pontoise, France

[9] Hosp St Marguerite, Rheumatol, Marseille, France

[10] Hosp Robert Debre, Internal Med, Infect Dis & Clin Immunol, Reims, France

[11] Univ Hosp St Etienne, Rheumatol, St Priest En Jarez, France

[12] Univ Hosp Pitie Salpetriere Charles Foix, Internal Med & Clin Immunol, Paris, France

[13] Hop Croix St Simon, Rheumatol & Internal Med, Paris, France

[14] St Germain En Laye Intercommunal Hosp Ctr, Internal Med, Poissy, France

[15] Hosp St Antoine, AP HP, Internal Med, Paris, France

[16] Hosp St Antoine, AP HP, Rheumatol, Paris, France

[17] Sorbonne Univ, Pitie Salpetriere Hosp, Pierre Louis Inst Epidemiol & Publ Hlth, Dept Rheumatol,AP HP,INSERM,UMRS 1136, Paris, France

[18] Bichat Claude Bernard Hosp, Internal Med, Paris, France

[19] Bichat Claude Bernard Hosp, Rheumatol, Paris, France

[20] Cochin Hosp, Internal Med, Paris, France

[21] Chu Bordeaux, Site Pellegrin, Rheumatol, Bordeaux, France

[22] Univ Lille, Inst Translat Res Inflammat, Referral Ctr Ctr Rare Syst Autoimmune Dis North &, Dept Internal Med & Clin Immunol,CHU Lille,INSERM, Lille, France

来源：

FRONTIERS IN MEDICINE | 2023年 / 10卷

关键词：

COVID-19; auto-immune diseases; inflammatory rheumatic diseases; rituximab; lupus; vasculitis; rheumatic and musculoskeletal diseases; CLINICAL CHARACTERISTICS; HOSPITALIZED-PATIENTS; OUTCOMES; PNEUMONIA; THERAPY;

D O I：

10.3389/fmed.2023.1152587

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionAutoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death. Materials and methodsTwo databases were analyzed: the EDS (Entrepot des Donnees de Sante, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case-control study within the EDS database to compare AIRD cases and non-AIRD controls. ResultsAmong 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08-1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68-1.81)]. ConclusionIn this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.

引用

页数：15

共 68 条

[1] Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients [J].